Modern technologies and biomedicine ambitions have given rise to new models of medical research, including population biobanking. One example of biobanking is brain banking, which refers to the collection and storage of brain and spinal cord samples for research into neurological diseases. Obviously, brain banking involves taking brains and tissue from deceased people, a fact which complicates the role of recruiters and makes consent a poor tool for stakeholders. After contextualising brain banking and considering the public health issues at stake, this article explores the legal definitions and demands of, and actual processes around, consent in England/Wales/Northern Ireland and authorisation in Scotland, articulating and evaluating their conceptual and practical differences. It then argues for an expanded but improved operation of 'authorisation' in the brain banking (and broader biobanking) setting, adopting 'solidarity' as our foundation and the improvement of the 'public good' our objective.
I. INTRODUCTION
Modern technologies and ambitions for biomedicine have given rise to new models of medical research. One such model is population biobanking, which is the practice of collecting tissue and data into a repository that can be used as a research tool by multiple researchers over a period of time. However, despite widespread pursuit of, and support for, biobanking, considerable uncertainty persists around how to most optimally structure the governance of, and participation in, biobanks. Significant debate has centred around how best to recruit participants, and whether consent could ever be 'informed'. 1 Some have argued for a more 'open' or 'broad' consent, and some for approaches that view consent as an ongoing process rather than a one-off event, 2 and others have argued for a retreat from consent (and consent language) altogether, 3 claiming that the more pertinent issues are those of 'control' and the advancement of the 'public good'. For a variety of reasons, it is argued, the consent paradigm's focus on the position and wellbeing of the individual participant/donor and his or her autonomy sits uncomfortably in the biobanking model, which is prospective, purposively indeterminate, and aimed at furthering the interests of, and benefit to, the community as a whole. 4 This lack of congruity is heightened in brain banking because one is there dealing with 'participants' who are deceased at the time of their donation. 5 The result is that third parties are more often and more directly drawn into the recruitment interaction. Participants are typically recruited in one of the following ways:
• an individual decides to donate, and records their wishes in an Advance Directive or some other format, and their relatives are engaged and counselled after their death; • an individual is approached by a donor programme or their palliative care team, and agrees to donate, making their wishes known, and their relatives are engaged and counselled after their death; 6 • an individual makes no decision about donation or at least fails to inform anyone of his/her wishes surrounding donation, and an individual's relatives may be approached about donation after their death, in which case the relatives become the primary decision-makers.
This recruitment process raises some important practical questions which are (or can be) influenced by the recruitment model used:
1. Who should consent in the absence of the expressed wishes of the deceased? 2. If the known wishes of the deceased conflict with those of the family, who prevails? 3. If re-consent is needed for new research, who should provide this, especially if the deceased gave the original consent?
This article follows from the AHRC-funded 'Banking (On) The Brain' (BOTB) project. 7 It examines the current framework for recruitment to brain banks in the UK. At the outset, it must be acknowledged that post mortem examination (PME) rates are declining, which translates into an inability to secure brains and brain tissue for research (ie: hindered recruitment). 8 Particular difficulties have been encountered in obtaining unaffected or 'normal' brain tissue, which acts as a necessary control in the investigation of disease 9 ; without sufficient quantities of both 'diseased' and 'normal' tissue, there is a real risk that research, which relies on numbers of statistical significance and control data, will be stifled or might lead to incorrect conclusions and improper solutions. 10 There are, of course, a variety of reasons for this decline, including historical ambivalence towards autopsies, 11 use of ownership models by families to claim possessory rights in bodies, 12 and the organ retention scandals of the late 1990s. 13 To these we would add the legislative frameworks under which recruitment now takes place.
In the following pages, after contextualising brain banking and justifying its characterisation as supporting the public good, we consider 'consent' under the Human Tissue Act 2004 (HTA 2004), 14 and 'authorisation' under the Human Tissue (Scotland) Act 2006 (HTSA 2006) . In doing so, we draw on secondary regulation from the Human Tissue Authority (HTA), 15 and have reference to recruitment strategies deployed by brain bankers. After exploring the demands and consequences of consent in England/ Wales/Northern Ireland and authorisation in Scotland, we argue for a more uniform shift from 'consent' to 'authorisation', with the caveat that we must ground 'authorisation' on a wider value base than currently prevails. We close by making a case for improving the operation of authorisation in the biobanking and brain banking context by operationalising 'solidarity', which would facilitate a shift in thinking about donation. It would retreat from the contested concept of donation as an altruistic gift, advancing the view that donation is rather a contribution to the wider social fabric (ie: to individual health and the health of future generations) that is owed.
II. PUBLIC GOODS AND PUBLIC HARMS
In this section, we argue that health is an important and valued 'public good' and we demonstrate that brain and neurological diseases are a serious and growing challenge to health. We also point to the instrumental role that brain banks-by providing well-curated samples of human tissue to a community of researchers-play in advancing knowledge about brain development and conditions that affect the brain, and developing effective treatments for same. These realities are important for justifying brain banking and the adoption of legal measures to support it.
A. Health as a 'Public Good'
A 'public good' is an end, outcome, or commodity which is 'non-rivalrous ', 16 or 'nonexcludable', 17 or both (ie: one person's use or enjoyment of such goods will neither negate nor diminish another person's enjoyment). 18 Applying these criteria in the 14 This applies to England, Wales, and Northern Ireland, though note that on 2 July 2013, the Welsh government adopted the Human Transplantation (Wales) Act 2013, which implements a 'soft opt-out' system for organ donation, whereby individuals will be presumed to have consented for their organs to be donated unless they have opted out. Under this system, donation will not take place if a relative or longstanding friend of the deceased objects on the basis of the deceased's views so long as a reasonable person would conclude that the relative or friend knows that the most recent prior-to-death view of the deceased on the matter of consent for donation was that of opposition: see s 4(4)). This Act comes into effect in 2015, and it is only applicable in relation to the donation of organs for transplantation, not organs donated for research purposes. 15 As authorised by HTA 2004, s 26(1), the HTA has produced nine Codes of Practice which articulate standards of conduct for persons carrying out activities within the remit of the HTA. The existing codes pertain to consent, donation of solid organ for transplantation, post mortem examination, anatomical examination, disposal of human tissue, donation of allogeneic bone marrow and peripheral blood stem cells for transplantation, public display, import and export of human bodies, body parts and tissue and research, and can be found at <http ://www. hta health context, we can say that one person's health does not necessarily diminish someone else's health, and one's achievement of health (or rather one's possession of health and vitality) does not in the normal course limit others' achievement of it; nobody in a population can be excluded from benefiting from a reduction in the risk of infectious disease, for example, and one person benefiting from this reduction in risk does not prevent anyone else from also benefiting. 19 Of course, these claims might be complicated when there is a need to access limited healthcare resources to achieve that health, but, as will be argued below, this public/private divide is blurring and becoming irrelevant to the characterisation of health as a public good. 20 Some go so far as to argue that health is a global public good because enhanced mobility, international trade linkages, information flows, and cross-border environmental threats have accelerated the extra-national transmission of disease and of behavioural and environmental health risks/determinants. 21 While we concur with this broader identification of public goods, it is not essential to our argument. Further and relatedly, while we concede that the substance of what is meant by 'in the public good' may evolve over time, 22 and that some manifestations of it might not easily co-exist, 23 we take it as uncontroversial that health is also in the public good. In this sense, we take 'in the public good' to mean an activity which will bring about some real social welfare enhancing benefit to a community or society at large.
Individual and community health are the fount of all other social ambitions and achievements; without health and some level of vitality, very little can be accomplished (ie: no wealth-generation activities like labour, production or innovation, and no social activities such as democratic engagement or cultural generation). Health is an important-and arguably the most important-constituent element of individual and community existence, and all societies must engage with and promote health or they risk failure. The fundamental importance of individual and community health is reflected by the amount of critical thought, political attention, social and legal architecture, and public money directed at their realisation. With respect to money note that the NHS typically represents one of the largest single national budget expenditures, 24 and its 2011/12 budget was £106 billion (approximately 8.4 per cent of GDP). 25 Of course, while most will agree that health is 'in the public good', rational agents may well disagree about how to define health or health benefits. This may give rise to difficulties in some contexts, but less so in the present one. If we accept that brain disease, and particularly degenerative brain and neural conditions, are rising and are affecting significant levels of the population, then it becomes much less contestable to state that the pursuit of treatments for such conditions is in the public good. How to decide on the type of research which should be pursued (ie: which conditions should be prioritised outside those which affect significant numbers) is a separate issue, but is nonetheless addressed briefly below.
B. Brain Diseases as a Pressing Public Harm
To state the obvious, health is diminished by injury and disease. Thus, we require social systems (ie: policies, practices, institutions, instruments) for monitoring, maintaining, and restoring health. In the UK, we have, inter alia, the NHS. Like most free-atpoint-of-service public health systems, the NHS began as an ambitious dream of universal care (and caring) which would serve to raise the relative welfare of society. 26 While ambitions for and expectations placed on the NHS have perhaps declined from their lofty antecedents, it is still expected to deliver reasonable health to the public through effective interventions delivered fairly and efficiently by competent professionals.
Of course, questions persist as to what this might mean in practice, particularly in light of the following:
• increasingly expensive technologies and treatments (from new, narrowly targeted and expensive drugs to IVF, etc.); • increasingly aged populations (imposing the treatment pressures of long-term and degenerative conditions); and • decreasing numbers of system contributors (in the form of taxable employed citizens).
Questions also persist about the implications of privatisation of some services traditionally provided by the NHS, a main point of concern being the consequences of such on standards of care, 27 and sharpening of health inequalities. 28 Answers to these questions are not obvious, but also are not pertinent to the argument. What is clear is that the NHS faces many difficult challenges as a result of changing demographics, demands, and disease patterns. Neurodegenerative and other neurological diseases in particular are cited as pressing concerns. In 2011, in the twenty-seven EU countries plus Norway, Iceland, and Switzerland ( population: 514 million), disorders of the brain-defined as including mental and neurological illnesses-were estimated as costing E798 billion per year. 29 This represents twentyfive per cent of the direct healthcare costs in Europe, with indirect costs adding to this figure. 30 A recent report estimated that the total cost of brain disorders in the UK in 2010 was E134 billion which included indirect costs, direct non-medical and direct healthcare costs. 31 In fact, the NHS is said to be facing a 'neurological time bomb' due to expanding disease burdens and patient demand. 32 The picture is similarly bleak at a global level, as it has been estimated that disorders of the brain account for thirteen per cent of the global disease prevalence, a level which surpasses both cardiovascular diseases and cancer. 33 And quite aside from the resource implications of these disorders, the human impact is profound; they have life-altering health and functionality implications for the patients, and cause social and relational fallout for families.
Ultimately, individual and community health are seriously threatened by diseases of the brain, and will be increasingly threatened in the future, and this in turn will place more and more pressure on already straining healthcare systems around the world. 34 As such, we can strongly claim that they are a pressing public harm which should be met by the pursuit of rationally connected public actions to bolster the public good that neurological and brain conditions diminish.
III. BRAIN BANKING AND INTERESTS IN CADAVERS
In this section, we argue that brain banking is such an action; it is in the public interest (ie: it supports in a very direct way the public good that is health), and any effort to regulate brain banking must be cognizant of the relative strengths of the interests at stake. 28 A. Brain Banking in the 'Public Interest' The above harm snapshot justifies our claim that it is in the 'public interest' to actively facilitate health research, and, more specifically, research into the workings of, and disorders affecting, the brain. We define 'public interest' as the aggregate interest of a populace and both the main objective and justification for democratically empowered political structures. 35 So acts 'in the public interest' are acts which are 'in the public good' (ie: which have real welfare-enhancing potential for publics).
We recognise that defining 'publics' or 'the public' to which benefit should accrue in a given context, and how many individuals an act needs to benefit for it to be deemed in 'the public interest', may give rise to controversy; in fact the difficulty of drawing boundaries on the 'public' in other contexts has been noted in detail elsewhere. 36 Nonetheless, given that brain diseases are non-discriminatory of 'publics' in the sense that they may affect any individual regardless of ethnicity, socio-economic background, gender, age, etc., the 'public' which may be affected by illnesses of the brain will be significant and will encompass the vast majority of the population. It follows that research on the brain is firmly within the public interest in the broadest sense.
Of course, with advances in genomics and the predictability of illnesses, including illnesses of the brain, the 'public' which may be affected by such diseases may be said to decrease. Similarly, in the rare diseases context, one might argue that the public affected is much smaller, making it questionable whether pursing treatments on such diseases is in the broader public benefit. However, both these claims can be countered. First, predictability is often not nearly as objective or accurate as the term suggests. Many factors can diminish or negate the predictability claimed in relation to genetic testing, including lifestyle and environmental factors, both of which might be imposed on the individual. Second, from an impact perspective, rare diseases have consequences for people well beyond the number of those afflicted. They place all manner of burdens and hardships on families and loved ones, sometimes both well before and well after onset of the disease in the patient. Thus, research on the brain does not just benefit those who may suffer from illness, rather it has an important relational aspect. All told, while the parameters of the 'public' can and have been contested elsewhere, it is reasonable to say that, given the prevalence, potential for harm and relational aspect of brain diseases, brain banking (and associated research) transcends the boundaries of the obviously concerned 'publics' and touches on a significant portion of the 'public'.
Ultimately, while we recognise that it can be difficult (or rather a matter of contestation) to define what is truly in the 'public interest', or what it means to respect the 'public interest', 37 we take it as relatively uncontroversial that it is in the public interest to actively promote and support public goods, and, as we have shown, health is a public good. Further, brain banking is an integral part of (brain and neurological) health research and thus it is in the public interest to maintain and support the donation of tissue to such banks. 38 Obviously, this argument is premised on the assumption that the banking undertaking and the research it facilitates is both ethically robust and scientifically sound. On this point, it should be noted that the operation of all tissue banks in the UK, including brain banks, is dependent on having the appropriate ethics approval from a relevant Research Ethics Committee, as well as NHS Research & Development approval. 39 A licensing scheme also applies under the Human Tissue Act 2004 to all tissue banks in England, Wales, and Northern Ireland, 40 ensuring that each bank meets appropriate ethical and safety standards. Scotland has also recently adopted a non-statutory accreditation scheme for the collection and storage of human tissue in NHS Scotland. Developed in consultation with NHS Scotland R&D Directors, NHS Scotland tissue bank managers, public partners, and Healthcare Improvement Scotland, the scheme seeks to ensure tissue banks adopt the highest possible professional standards. 41 Additionally, all brain banks in the UK are part of the UK Brain Bank Network, which seeks inter alia to put in place common 'gold' standards for brain banking, including harmonised procedures for consent and stewardship across the UK. 42 Finally, researchers seeking to obtain tissue from MRC-funded brain banks must also apply to the bank for permission. This usually results in an assessment of the application based on its scientific merits, as well as the likelihood of it giving rise to ethical issues. 43 Ethically approved research using samples obtained from ethically robust brain banks will generate knowledge that will: • contribute to deeper understandings of the brain and human body;
• illuminate the causes and progression of diseases;
• contribute to more effective and less invasive cures, treatments, and/or management strategies for the afflicted; and • inform more cost-efficient and effective ways of structuring and delivering healthcare system responses.
Further, the knowledge created will be probed and built-upon thereby expanding human knowledge beyond that envisioned by the initial cost and contribution. 44 The long-term aggregate impact of brain banks will be to reduce human suffering and to promote (and realise) better health and human functionality. 45 In fact, biobanks (of which brain banks are just one genre) have already been defended as valuable resources for the public interest:
[W]e offer the following proposition: scientifically sound, ethically robust research using biobanks is manifestly in the public interest. We would, in fact, go further and suggest that there is a positive moral obligation to promote the use of these research resources in ways that, in turn promote the public interest. This can only happen through access. The imperative, then, is to promote access on sound scientific, ethical, and legal principles. 46 While brain banks have already been instrumental in furthering our understanding of central nervous system function and neurological diseases like Alzheimer's, Parkinson's, and Multiple Sclerosis, 47 and in recognising new types of diseases, 48 their benefits are not necessarily expected to be enjoyed by the individuals who participate/ donate. A long view of the research investment is evident, wherein the collective is prioritised over the individual. In this way, brain banks serve as mechanisms of intergenerational justice (ie: the present generation contributes positively to the utility and contours of such a framework require further investigation and are beyond the scope of this paper. It is enough for our argument to highlight the already stringent mechanisms of ethical approval that are required, and to note that these may and could be strengthened to align more closely with public objectives, thereby giving the 'public' a more active role in the process as befits the solidarity model. 44 It is re-used and reconsidered, a process which further verifies knowledge and adds value to it: M Callon and G Bowker, n 38, above, who, at 401, argue that scientific knowledge ' . . . is a durable good, not destroyed or altered by its use. Even better, the more it is used the more its value increases because it proves its fecundity, widens the scope of its applications, and becomes richer'. 45 For a discussion of the scientific knowledge being generated by such networks, see M Callon and G Bowker, in n 38 above, better health of future generations). In our view, this enhances the status of brain banks as being in the public interest for it permits greater benefits to emerge for a wider community over time.
We concede that the state's obligation to foster brain banking depends on its rational connection (or necessity) to the public good sought to be advanced (eg: health for individuals and publics). In this respect, it is notable that while technological advances allow improved disease progress monitoring in living brains, cell cultures, and animal models, 49 developments have not rendered the need for examination of cadaveric brains obsolete. 50 If anything, given its support of genetics and functional genomics-which themselves have given rise to techniques which facilitate better understandings of disease pathogenesis and potential therapeutic targets-PME and removal of tissue for brain banks is more crucial than ever for investigating neurological diseases and providing evidence of the efficacy of therapies. 51 Thus, it is vital that we have sufficient samples available in order to advance neurological understandings. In summary, the public's interest in brains is strong and the connection between procuring them, generating relevant scientific and health knowledge, and improving health is all rationally (indeed closely) connected.
The presence of commercialisation might be used to undermine the characterisation of brain banking as in the public interest. Private (commercial) entities do and will continue to play an integral role in the realisation of improved health. The realities of drug innovation are that it is time and cost-intensive beyond the capacity of purely public support. This, combined with the large and potentially lucrative market for neurological treatments means that commercial entities will be interested and involved in brain and neurological research, and, to a lesser extent, in the formation and maintenance of brain banks to support that research. However, commercial involvement does not negate the public nature of the problem, the public interest in brain banking (and research), nor the public good character of health. 52 The primary consequence of commercial involvement is that some (or all) of the eventual treatments may be subject to patent protection (or intellectual property enclosure), thereby rendering them temporarily excludable, or selectively available through licensing strategies or pricing regimes. This is, of course, not ideal; it means that individuals will be asked/encouraged/required to donate for the public good in the absence of an assurance that their donation will result in something instrumental 49 See J Bell and others, n 5 above, at 498, and H Kretzschmar, n 34 above, at 71. that will be immediately available to everyone equally. However, two matters serve to undermine this challenge. First, although the interplay of regimes is such that intellectual property diminishes access, this diminishment must be viewed as temporary. The fact is that the knowledge will eventually fall completely into the public domain, and in the preceding period treatments will be available to patients, although their availability might be narrowed by costs to the bearers of healthcare funding (eg: taxpayers and/or individuals). Second, given the gravity of the health problem society faces, it behoves us to work within the confines of the legal order that has evolved in this context, even if this means the sub-optimal availability of treatments (which we readily admit, but which is not at all remedied by using the contested involvement of the intellectual property regime to deny the existence of brain banking as being in the public interest).
Given the ambiguous role of commercialisation, scientific knowledge is sometimes described as an 'impure' public good, in the sense that if there is patent or other IP protection the knowledge becomes temporarily excludable (and therefore fails the nonexcludability criteria). 53 Some have pointed to general public misgivings around commercial involvement in and profit arising from such research, noting the common perception of donation as a 'gift' and the concomitant assumption that it will not be associated a financial return to another. 54 To alleviate these misgivings, they have advanced benefit-sharing models based on the Newfoundland and Labrador Model. 55 This model requires a proposal for benefit sharing to be provided along with the application for ethical approval. Obviously, a similar framework could inform brain bank resource access, thereby ensuring not only that only approved research which was deemed to be in the public interest is carried out, but also that measurable benefits are returned to the community, even when private enterprises are accessing the resource.
In any event, our claim is simply that health research conducted using samples provided by brain banks has the potential to generate knowledge which will facilitate the understanding of diseases and the development of treatments. This is undoubtedly of benefit to individuals and to levels of community health and functionality. 56 Hence, it is in the public interest to promote the generation of such knowledge and brain banks and associated research should therefore be actively encouraged, or at the very least not unnecessarily impeded. . 56 Of course, one might question whether any public good is realised without some private and/or commercial contribution and therefore interference. As such, the interplay of commercial interests here makes no difference to the characterisation of health as a 'public good', or to brain banks as being in the 'public interest'.
B. Ranking the Stakeholders' Interests Before proceeding to a critique of how the law supports brain banking, it is important to consider who has or may assert an interest in the material that is the 'life-blood' of brain banks (ie: cadavers and their brains). We suggest that the (formerly) living individual, the surviving family, and the public may all assert some interest, and the relative strength and foundation of that interest is considered below.
The first interest-holder is the deceased individual. While alive, that individual had interests and rights enforceable against others, including the state and family members, though none of these rights would have been absolute. Additionally, the deceased can, while alive, express testamentary wishes in relation to a variety of matters which will be enforceable after death through the estate using legal/state mechanisms (eg: disposition of property, use of personal likeness, disposition of body), although again there are limits as to what can be expected/demanded. 57 In complying with these wishes/instructions, we might claim that we are vindicating the individual's autonomy, but this is not entirely accurate. Presumably, an autonomous decision was made while alive, but at the time of ( posthumous) enforcement, it is not autonomy that we are vindicating for the deceased ceases to 'be' and nothing can physically or emotionally harm or improve his or her position. This has led to compelling arguments that all of the deceased's autonomy and interests (together with the ability to personally enforce them) evaporate at death, and there are no obvious residual interests to defend. 58 Bolstering this position is jurisprudence to the effect that human rights cannot be claimed or enforced by or on behalf of someone who is not living. 59 One might argue that it is a dignity-based respect for the deceased that compels us to comply with the deceased's wishes (and to legislate compliance through instruments like the HTA 2004 and HTSA 2006), but again the deceased remains indifferent to that dignity. He or she has none to claim or display. Ultimately, it might be more the survivors' remembrance of that (former) autonomy and dignity that is being respected. It is a claim by the survivors to that intangible that connects the past to the present and the future (the deceased to the living and the as-yet unrealised descendants). While the maintenance of such connections has value, one might question whether they seriously serve to strengthen a deceased's interest in his or her cadaver, which must be viewed as weak. It might serve to favourably place the survivors' interests in the cadaver, but more tangible and legally recognisable interests might be desired for purposes of ranking claims. With respect to survivors, it is the deceased's family who will, in the normal course, have the best interest in the cadaver. Grieving relatives and loved ones will have a strong emotional connection to the deceased, and thus, the current practice understandably seeks to put their interests centre-stage; this is a noble and compassionate response. However, while we acknowledge that family members can have enforceable (legal) interests in relation to the living individual (interests that are enforceable against the state, against others, and against the individual him or herself ), those interests diminish upon the individual's death, or rather the right to enforce those interests diminish, often to the point of nullity (although we acknowledge that claims against an estate can persist). With respect to the actual corpse, family members might invoke ECHR Article 8 (right to private and family life) and/or Article 9 (right to freedom of thought, consciences, or religion) to ensure its disposal in a certain way, 60 but the key point is that their legally recognised interest in the cadaver is restricted to possession for disposal (eg: burial or cremation). 61 The operation of these provisions is aimed at vindicating the deceased's (and more often the survivors') rights to have spiritual/religious and ceremonial expectations/conditions met (and so ties into the dignity and memorial interests articulated above). However, even then it has been held that the public interest might override their interests and/or stated position. 62 Finally, there is the public's interest in cadavers, which are grounded in state obligations to advance individual and public health, which, in turn, strengthen the social fabric and viability of communities. The state's interest in public health has long been considered an important public interest, and a legitimate target for state action. 63 The disposition of cadavers as part of that action ensures that cadavers are properly/safely disposed of so as not to pollute public spaces and essential utilities, and the state's allocation of cadavers for use serves to: Indeed, the value of PMEs has led some to argue that medical authorities should reject the classification of PMEs as elective and adopt them as a professional obligation, 68 although this might have unsustainable resource allocation consequences. The state's interest in health also engages some of its responsibilities under human rights law, most particularly those implicated by the so-called right to health; the right to the highest attainable standard of physical and mental health, and to a standard of living adequate for health and basic needs is contained in numerous international instruments. 69 This right may be inferred from Article 2 of the European Convention on Human Rights (1950), which states:
Everyone's right to life shall be protected by law. No one shall be deprived of his life intentionally save in the execution of a sentence of a court following his conviction of a crime for which this penalty is provided by law. Importantly, the 'right to health' is increasingly seen as essential to achieving equitable societies. It has informed health policy reforms, 70 and constitutional provisions linked to the right to life, to dignity, and to physical integrity. 71 In combination with the legal and social entitlements that Europeans generally enjoy (and expect), 72 the effect of this right is that individuals have higher aspirations than ever before for achieving and sustaining good health, including health in old age, 73 and this will surely continue in future generations.
To make this right effective, the state, through health authorities, must make suitable and timely treatment options available. To date, jurisprudence drawing on the right to health has imposed on states and health authorities the obligation to:
• ensure that hospitals employ competent staff who are trained and work to a professional level within systems that protect patients; 74 • avoid putting an individual's life at risk through the denial of care that they would have made available to the larger population; 75 • restructure national healthcare systems to improve care. 76 Essentially, states and health authorities are expected to achieve more and to deliver better health outcomes (usually with fewer resources), and this will be true with respect to burdensome and widely experienced neurological diseases. The use of cadavers is a vital component of fulfilling that expectation. Indeed, the importance of deceased donation was recently emphasised in the Human Transplantation of Organs (Wales) Act 2013, which introduces a soft opt-out system for organ donation for transplantation in Wales. Interestingly, s. 2 of the Act imposes a duty on Welsh Ministers to 'promote transplantation as a means of improving the health of the people of Wales'. This marks a firm commitment to improving the health of people through cadaveric donation. Similar arguments could be made to justify promotion of donation for research; while such donation does not have the immediate and personal effect as in transplantation, it has the potential to generate knowledge which could improve the condition of generations (and may reduce the demand for transplantation which now wildly exceeds supply).
Given the above, we argue that the public (ie: the collective as represented by the state) has the greatest/strongest interest in cadavers and their disposition. The deceased's interests and those of the surviving family might be personal, sentimental, or community-bonding, and they are largely dignity-based. By contrast, the public's interests are utilitarian, instrumental, and pressing. human rights responsibilities and expectations, but they are also community-bonding. Realisation of those public interests will generate great advantage for a great number of people, and will also enhance the dignity of those people (by giving them better health, better lives, and better deaths).
IV. THE REGULATORY FRAMEWORK FOR BRAIN BANK
RECRUITMENT The above demonstrates that, when crafting regulation governing the life scienceswhich are strongly linked to advances in healthcare and health-it is vital that we think about:
1. the 'public good' and how we can better advance it; 2. what we expect of medical research and the scientific knowledge generated therefrom; 3. whether we are willing to contribute sufficiently to the enterprise to fulfil the great expectations we have placed in it.
As part of that exercise, it is axiomatic that the applicable legal framework be designed to shape behaviour to facilitate the public good, not frustrate it, and to recognise and accurately reflect the interests at stake. In terms of shaping behaviour, the legal framework should facilitate donation by ensuring that an individual's express wish to donate is carried out and not overridden by third party interests. Individuals should be made aware that in the event of uncertainty, there would be a presumption in favour of donation. This would encourage individuals to think seriously about donation and facilitate wider (and maybe deeper) public thinking around medical research. In other contexts, rewards are provided in order to encourage donation such as providing cheaper healthcare for those who donate samples for research purposes. 77 However, such schemes have been challenged on grounds that they may be exploitative or derogatory of 'true' consent. 78 While we do not necessarily agree with this challenge, we do not recommend a rewards system for brain donation in part because of the difficulties arising from the fact that the donor would be deceased at the time of donation. An important aspect of our approach is the attitudinal shift that solidarity could bring: individuals would come to better appreciate the individual obligations that they bear and to recognise donation as a contribution to health, including their own, all of which might result in stronger community sentiment towards donation. In short, for the public good to be truly acknowledged in biolaw, the legal framework must be designed to (strongly) encourage individual contribution. 79 Given all of the above, two questions are implicated: (1) How has the law been fashioned? (2) How is it working to support brain banking? In this section, we explore those questions, focusing on the regulatory frameworks in England/Wales/ Northern Ireland and Scotland, respectively. After articulating the conceptual foundation of the legal regimes, we examine the consent and authorisation models more closely, highlighting intended differences, and then the problematic role of families in brain bank recruitment, which tends to negate those differences.
A. Conceptual Foundations of the Legislative Frameworks
The existing framework for the donation of human tissue, including brain tissue, emerged as a result of public concern (and outrage) over non-consensual post mortem removal and retention of organs in both England and Scotland. 80 Investigations undertaken at the time found that the brain was the organ most often retained, although most brains were retained for diagnostic rather than research purposes. 81 They were retained as a result of genuine beliefs that retention was in the 'public interest', and erroneous beliefs that the Coroner or Procurator Fiscal could authorise retention of organs which had no bearing on the cause of death. 82 Interestingly, the primary cause of distress was the lack of information and consultation rather than the retention itself. 83 In any event, the public outcry resulted in a heavy emphasis by policymakers and legislative reformers on ensuring disclosure and clearer decisional frameworks for post mortem retention of tissue. The resultant legislative frameworks were heavily shaped by 'autonomy' and 'risk', concepts that place the individual at the centre of all things and emphasise the need to 'protect' people 'from' the medical establishment and the harms that might follow from research participation.
Autonomy acknowledges the human capacity (and desire) for self-determination and self-rule. It values people as physical, psychological, economical, and legal entities individuated from others, and respect for autonomy involves creating spaces for individuals to make decisions relating to themselves with as little interference (or coercion 79 Recall that the public's compelling interests in cadavers are currently being met with declining PME rates with the result that brain banks struggle with recruitment. or duress) as possible. 84 It therefore serves as a foundation for rights relating to physical integrity, freedom from coercion, and privacy. 85 Risk is the potential or probability of some event or occurrence happening that is negative or harmful to individuals and communities (eg: something that destroys, damages, injures, unbalances, challenges, questions, or affronts). 86 Risk discourses have increased in society as people, driven by autonomy, wish to control more and more of the lived environment and their destinies within it. As this has happened, the regulatory concern with risk has also climbed, with much regulation aimed at minimising deviations from the (agreed) norm. 87 Given the above, the doctrines of consent and, latterly, authorisation have emerged. In the medical context, consent grew from a desire to protect individuals against harm or unwanted invasions of bodily integrity. 88 In the research context, it developed with the goal of ensuring respect for individuals and avoiding a repetition of the medico-scientific atrocities committed during World War II. 89 It has evolved as a means to facilitate the exercise of individual autonomy with respect to actions relating to one's body (offering individuals some control over the risks to which they expose themselves), and authorisation has inarguably taken up that same cause. In both cases, a key ambition is to inform individuals and allow them to make decisions relevant to risks, and their inclusion in regulation typically contains mandated assessments of risk or harm manifestation. It must also be acknowledged that consent has a double effect in that obtaining it serves not only to protect patients but also to protect medical practitioners such as doctors, researchers, etc. from unwanted litigation. 90 What is significant is the origin of the tissue (from humans) and the status of the donor at the moment of donation; brain tissue is considered to be tissue from a deceased person.
B. Decisional Mechanisms Under Both Acts
The HTA 2004 relies on a traditional consent model in that, after provision of relevant information addressing risks and benefits of the particular intervention (here donation), the 'appropriate consent' must be given. The 'appropriateness' is determined having reference to whether the statutorily required person has given the consent, and this depends on whether the subject (or donor) is an adult, an adult without capacity, or a child. For example, under section 3(6), the appropriate consent of an adult is manifested as his or her decision in force immediately before death. If no such decision was made (or is known), then the appropriate consent is the decision of his or her 'nominated person' under section 4. If he or she has not nominated a decision-maker, then the appropriate consent is that of the person who stands in the most authoritative 'qualifying relationship' to him or her immediately prior to death. The ranking of qualifying persons is set out in section 27(4) as follows: spouse or partner; parent or child; brother or sister; grandparent or grandchild; child of a person the person concerned brother or sister; stepfather or stepmother; half-brother or half-sister; friend of longstanding. The Act offers nothing by way of criteria for shaping individual choices.
As with consent, 'authorisation' under the HTSA 2006 is a decisional model driven by autonomy, risk, and the individual, and authorisation must be given by the 'appropriate person'. This varies depending on whether the donor is an adult, a child 12 years or over, or a child under 12 years of age. 92 Like the consent model, authorisation draws heavily on risk. 93 The term 'authorisation', however, was preferred over that of consent because it was felt to better capture the actual interests and circumstances at play. The influential McLean Report 94 defended its preference as follows:
• Authorisation would reinforce the belief (in everyone concerned) that individuals could and should make decisions about their own bodies, and that these decisions should be enforced. 95 • While 'authorisation' better captures the right of donors (or relatives) to receive full information, it preserves their right to decline certain details while still being able to make an enforceable/lawful decision; authorisation better balances the need for decision-makers to receive sufficient information to make a judgment and for staff to be more sensitive around the provision of information. 96 which come with parenthood insofar as it signals their rights against third parties who might try to interfere with family relationships. 97 In short, 'authorisation' was erected as an autonomy-based approach which has the primary goal of ensuring that the wishes of the deceased are enforced, but which has the ancillary aim of reducing the amount of information which decision-makers need in order to make an enforceable decision, whether that decision-maker is the deceased who may give authorisation prior to death, or surviving family members thereafter. So conceived, 'authorisation' is more suitable than 'consent' in the brain banking context, which implicates deceased individuals, for at least four reasons.
First, a key ambition of consent, in addition to those noted above, is to protect the physical integrity interests of the living. 98 However, this ambition has little relevance in the cadaveric context. The reality is that the human corpse does not remain intact but rather naturally decomposes. 99 Thus, there can be no legitimate interest in physical integrity after death. Moreover, because bodies must be buried or cremated, there can also be no expectation of inviolability. As such, one of the primary interests intended to be protected by consent is not directly engaged in deceased donation, 100 and therefore, it may not be the most appropriate legal mechanism.
Second, as articulated in the McLean Report, authorisation is intended to emphasise that the decision to donate does and should originate from the person's own volition. It is intended to signal a firmer commitment to respecting the expression that the individual made when alive. Indeed, it has been emphasised that authorisation is intended to more clearly convey the idea that people have the right to express during their lifetime their wishes about what should happen to their bodies after death, and that they should be able to expect that those wishes will be respected. 101 This suggests a more active role for the donor and a greater commitment to self-determination. 102 Third, it serves to ease the informational burden on all parties. This is appropriate in two respects. First, decisions need to be taken very soon after a person's death; the brain deteriorates quickly so donation must be carried out within the first few days. 103 Authorisation acknowledges that the donor and/or relatives may not want to receive detailed information about the donation procedure, and it gives recruiters discretion 97 should ever let others make determinations over another's body. In the event that we do, and clearly the HTA 2004 and HTSA 2006 provide that we do, the question of to whom that power falls is one that we may not have answered correctly. For more on deceased donation, see K Mason and G Laurie, n 13 above. 103 The interval between death and post-mortem varies depending on legal and resource constraints. In the MRC Sudden Death Brain and Tissue Bank, the interval was measured at between 28 and 140 h with a about the amount and specificity of information which they provide to donors/relatives should these parties agree to this, though of course recruiters must still give sufficient information to allow a decision to be made. Second, it acknowledges that some information around the purposes of tissue use (and thus possible longer term risks) cannot be known at the time of recruitment or donation (ie: it better caters for situations where research uses may not be fully known and where research may develop in a different manner than originally conceived). 104 In both cases, it signals that donation is still permitted provided the authorising person has sufficient information to make a decision. Fourth, and following on from the third reason, authorisation diminishes the need for re-contact, or reduces the circumstances under which re-contact and new authorisations will be necessary, which, in the brain banking case, would necessarily implicate third parties. Indeed, the Organ Donation Taskforce has opined that consent requirements are not fulfilled where relatives have to make the decision and are unclear as to what the donor would have wished. 105 The Taskforce claimed that the process is more appropriately viewed as an act of 'authorisation', 106 again reinforcing the distinction between the two concepts. To alleviate the third party involvement complication, one might draft consent forms very broadly so as to cover many potential uses, but this challenges the 'informedness' on which consent is founded.
The consequence of the above is that there are important conceptual differences between consent and authorisation. While both advance the ethical interests of decisional integrity, they do not demand uniform or common practices; they might be viewed as ethically 'equivalent' rather than 'equal', and so might be held up as an example of 'harmonised' rather than 'standardised' approaches to conduct (ie: as nonstandardised practices that are equally acceptable and effective). 107 Unfortunately for recruiters in Scotland, the HTA and Scottish authorities (and perhaps patients) seem to view consent and authorisation as convergent and standardised, and so performed in largely the same manner with the same steps and tools. While the regulator's aim is to ensure 'continuation of the arrangements for sharing organs and tissue across the UK', 108 the result is that authorisation does not do the work it might otherwise accomplish; like consent, it leaves significant scope for family interference in donation decisions, thereby prioritising family affecting interests over those of the donor and the public.
C. Divergence between Rules and Practice
The lapse of time between the deceased's expression of giving and the act of donation, combined with the absence of the donor at the actual time of the donation, results in a peculiar operation of consent/authorisation whereby the donor can become, and often is, marginalised. Unless an Advanced Directive is operable or the express wishes of the deceased are otherwise known to the physician(s) involved in the donor's palliative care or post-palliative handling, brain bank recruiters will have to solicit and comply with the wishes of a third party, which usually means a family member or members. The difficulty of their job is compounded by the fact that decisions need to be taken very soon after a person's death. These can be emotionally charged days, and the family may not be equipped to deal with decisions in relation to donation and dissection.
The statutes clearly identify the order of those who have decisional priority, placing the deceased at the top. 109 However, even in cases where a deceased person has expressed a clear wish to donate his or her brain or other tissue, those wishes will not be carried out by physicians/researchers in the face of objections by family members. 110 In short, despite an absence of any statutory veto, family members (sometimes regardless of where they rank in the decisional hierarchy) may still, and do, veto deceased donation decisions properly made and recorded, 111 a scenario which has been described as a 'double veto'. 112 This of course does nothing to respect the decision of the deceased who, while alive, made a reasoned and morally conscious decision about their death and the disposition of their body (and its parts); presumably, they wanted to contribute in some way to society through research in keeping with their duties under the social contract model. It also fails to recognise and enforce the statutory hierarchy of authority in situations where there are conflicting positions among the survivors.
While this deferential seems unjustified under both consent and authorisation models, it is particularly contrary to the latter, which is intended to signal a stronger commitment to carry out a deceased donor's wishes. The McLean Report was adamant that those wishes should be paramount, stating that they should be respected 'unless there is reason to believe that the deceased had a change of mind before (2) Hospital Autopsies: performed when the cause of death is known and a death certificate can be issued, but specific clinical questions relating to diagnosis or treatment modalities are implicated; (3) Family Autopsies: performed at the request of the family. While no family consent (or knowledge) is required to undertake a Coroner's or Procurator Fiscal's autopsy, the public authority is functus officio thereafter so consent is required before the pathologist can retain tissue for research. Family consent is also required under the other types of autopsies, which also require consent for the conduct of the autopsies themselves. If families demand return of the body and its associated tissue, they have a right to possession for the limited purpose of burial or cremation. 111 BOTB Project, Roundtable Workshops, 4 April 2012 and 19 September 2012. 112 The individual donor gets a veto (eg a right to refuse donation despite the family desiring them to do so), and family members get a veto (eg a right to effectively block donation despite an express wish to donate by the deceased): see T Wilkinson, n 58 above, at 587. death'. 113 Indeed, the McLean Report was specifically critical of the old practice of giving priority to family wishes:
Very often interpretation of the law has gone beyond its strict requirements. Doctors will virtually always ask relatives actively to agree to the use of the dead body, rather than, simply asking about the wishes of the deceased. While this practice is understandable given the circumstances, it fails spectacularly to respect the competently expressed wishes of the person now deceased. 114 [emphasis added] It recommended that:
the expressed wishes of the individual adult, competently made before death, should take priority over the wishes of surviving relatives. The current legal requirement to discover whether or not this agreement has been withdrawn should remain, but it must be clear that the relatives have no legal role in circumstances where the deceased had made known, and not retracted, his or her wishes . . . . An important concomitant of this recommendation to be a campaign directed at those who may wish to make such a declaration to encourage them to discuss their wishes freely and fully with those who will ultimately be asked about the deceased's intentions . . . 115
Despite the above, this deferential approach has both some commendable practical consequences and some regulatory support. With respect to the former, it is a pragmatic and sensitive approach to dealing with bereaved families. Medical practitioners have no wish to compound the emotional difficulties of mourning families, and they have strong self-interest in not embroiling themselves in unseemly disputes over the use of a deceased family member's body, particularly with the retained body parts scandal so recently in the past. Thus, as a simple matter of relational harmony and reputational preservation, and indeed as an act of solidarity with the bereaved family, this approach makes sense on the ground. In the context of organ donation for transplantation, the Scottish government has stated:
Few, if any, transplant surgeons would go against the wishes of a family. Whilst there are unlikely to be any repercussions against a surgeon who removed organs in the face of family objections from a person who wished to be a donor, there are few surgeons who would add to the stress of a grieving family by acting contrary to their wishes. Negative publicity from such an act would also have a detrimental effect on organ donation. 116 Additionally, this approach permits an operational flexibility, allowing the physician (or recruiter) to exercise personal and professional judgment about how to proceed in each case. In short, sensitivity and respect are cornerstones of the interaction; not respect for the deceased but for those who remain. Such respect should be a fundamental element of the physician's (and recruiter's) professional duties, and a formative part of the professional team's interactions with patients and families. It reflects a valuable civility that has been encouraged by the post-paternalistic turn in medical culture; whereas practitioners once decided with little or no consultation what was in the interest of the patient, patients now are expected to be more actively involved in treatment decisions through conversations about their care/treatment. With respect to regulatory support, the deferential approach is acknowledged by the HTA's Code of Practice I: Consent. Applicable to both the English/Welsh/Northern Irish and Scottish frameworks, it states that if a deceased person or nominated representative has consented to donation but those close to the deceased object, a healthcare professional should discuss the matter sensitively with the parties, should encourage the objector(s) to accept the wishes of the deceased, and should be informed that they have no right to veto these wishes. 117 It goes on to state, that in such circumstances a practitioner should consider 'the impact of going ahead with a procedure in light of strong opposition of the family, despite the legal basis for doing so'. 118 This inconsistency (between statute and practice guidance) is also evident in the Code's guidance relating to child donation in cases where the wishes of the parents or guardians conflict. It states that it is sufficient for one person in a position of parental responsibility to give consent to donation of a deceased child's tissue/organs, but then advises that:
The issue should be discussed fully with relatives and careful thought should be given as to whether to proceed if a disagreement arises between parents or family members. Any previously stated wishes of the deceased child should be considered, taking into account their age and understanding. 119
The real-world consequence is that, regardless of whether HTA 2004 'consent' or HTSA 2006 'authorisation' is relied on, neither legal mechanism is strictly enforced in the face of objections by family members, or conflicts within the family. 120
V. SOLIDARITY AND AN EMPHASIS ON THE 'PUBLIC'
IN BRAIN BANKING Although both the HTA 2004 and HTSA 2006 are grounded on autonomy and risk, and on the decisional authority of the individual, with authorisation intended to be even more autonomy-confirming than consent, practices on the ground have served to erode the differences between consent and authorisation, and to weaken the operation of both mechanisms insofar as recruiters are challenged by survivor opposition in the face of deceased consent/authorisation. While this might be seen to contribute to a more cooperative decision-making process around the use of bodies, it has had the real-world effect of blocking donation in the face of any objections by survivors. Ironically, the autonomy interest that frames the whole regime gets frustrated and the regulation fails to deliver on its promise to the deceased and the scientific undertaking. We suggest an approach more sensitive to the obvious and important 'public interest' aspects of brain banking, which are currently under-emphasised in the legislation and under-operationalised in practice. 121
A. A Value Foundation to Support the Public Interest
To make a real impact, the public interest must be given a role more in keeping with its significance (ie: given the increasingly high statistics and incidence of brain disease, it is imperative that research in this area is actively supported and that the public benefits are both emphasised and realised). There is thus a need to recognise the 'public' as an important stake-holder in the donation framework. This can only be achieved if the value-base underpinning the human tissue use regime is broadened. 122 In particular, 'solidarity' should be deployed as an action-and decision-guiding value in relation to the dead body; indeed, it should be given a prominence that is at least equivalent to other guiding values, including autonomy. 123 Solidarity has been defined as encompassing the following interrelated and mutually enhancing virtue-propositions 124 :
• Solidarity prioritises community by recognising that individuals are naturally and irrevocably embedded in social contexts; they are in a state of interrelationship or interconnectedness with individuals, groups, and society. • Solidarity emphasises equality and active promotion of welfare through its grounding in compassion, fraternity, and a genuine interest in the wellbeing of others, the ultimate goal being to construct, through personal and collective actions, both a just and decent or fair society. • As a result of our inclusion in societies and the complex of social relationships and values that is needed to realise standards of decency and justice within societies, solidarity emphasises the virtue of duties over rights; duties flowing from and towards individuals and communities that may require collective interests and public goods to take priority over the interest of individuals or sub-collectives.
So conceptualised, solidarity helps us characterise participation in brain banking as a beneficial opportunity, if not an obligation, to contribute to individual and public health beyond one's lifetime; it characterises participation as a legacy which contributes to intergenerational justice by enabling the health of future generations, and, as such, is a means to advance human wellbeing more generally. 125 If solidarity is better integrated into the legislative regime and the decisions that it structures, a new interaction can be framed. 126 And this interaction might better close the gap between levels of claimed support for research and the opportunity to make a contribution, and actual participation in research. 127 In a recent report commissioned by the Nuffield Council, the authors conceive of solidarity as signifying a collective commitment to carry 'costs' (financial, social, emotional, or otherwise) to assist others that require individual actions and collective commitment. 128 The report offers a three-tier approach to how individuals might interact with solidarity: 129 • Tier-1: Interpersonal: At base, solidarity is viewed as an expression of willingness to carry costs to help others with whom a person recognises similarity, sameness, or symmetry. It demands actions by individuals to help other individuals within a group or community who share certain things in common with them. • Tier-2: Group Internalisation: This solidarity arises when certain action elements of solidarity become engrained in a group (ie: come to represent an aspect of 'good conduct'), and so evolve into forms of institutionalisation. At this level, solidarity can be defined as 'manifestations of a collective community to carry costs to assist others who are all linked by means of a shared situation or cause', 130 and a common example of this is self-help or patient groups. This framework is useful for thinking about where solidarity needs to be introduced and how it might be embedded to reorient public perceptions about, and the regulatory regime applicable to, brain banking, and we shall return to it below. Suffice to say presently, we believe that shifting both participation levels in biobanks and regulatory frameworks demands two interrelated movements: first, the public interest must be understood in a more active sense which not only recognises rights, but also duties (ie: it must be understood as demanding positive efforts on the part of individuals as a component of their social citizenship); and, second, the moral or value-foundation of the public interest (and public goods) must be given a more prominent role, both generally and in individual conversations (such as that between physician/recruiter and patient/family). Solidarity offers a valuable touchstone for undertaking or facilitating these movements.
B. Operationalising Solidarity in Brain Banking
Conceptualising participation in brain banking as an act of solidarity justified (if not demanded) by the public interest encourages a shift towards greater consideration of the public good aspect of the enterprise. So grounded, the implications for brain banks might be that a system of mandatory donation to brain banks could be justified on utilitarian, virtue, and international human rights grounds. 131 While mandatory donation might be considered problematic by some, particularly in our prevailing individualistic social context, additionally so in this context given the deep personal and growing cultural significance of the brain, 132 it is not without its supporters. A mandatory system has been justified in other contexts on the grounds that individuals receive public health benefits stemming from brain and other life science research, and they must therefore be viewed as accepting those benefits on the understanding that they may need to contribute to the 'public good' by donating post mortem tissue for such research. Indeed, it has been argued that if we accept the benefits of medical research (eg: antibiotics and other medicines), then we have an obligation to contribute to social practice which produce those benefits. 133 Where that contribution is only made after death, the argument is even stronger, 134 although such a system would need to incorporate provisions permitting individuals to object to donation in keeping with other human rights (eg: freedom of religion), which would operate in exceptional circumstances.
Despite the defensibility of mandatory donation, we are not arguing for this, and the sheer cost and personnel demands would, in any event, make it unsustainable. Further, it should be acknowledged that brain banks do not require donation from all individuals; they merely need an increase in current donation rates, particularly of 'normal' brains. Thus, we propose a regime which gives preference to public needs, and which justifies those preferences with reference to the public good that is health, the public interest in its achievement, and acknowledgement of the 'social contract' which we all enter into. The social contract theory recognises that individuals gain benefits from society (and this is certainly so in a democratic welfare state with a free-at-point-of-service healthcare system), and it holds that individuals must therefore also give back to society. 135 As part of that, they must accept that their interests may sometimes be compromised for the 'public good'; and what less intrusive time to compromise those individual interests than after death when the compromise will mean nothing to the individual who is being asked/commanded to contribute? If we accept that individuals and society are in a contractual relationship in which each entity must not only receive but should also give, the question becomes: How can we better embed the notion that it is a social responsibility to support biobanking? Here we can draw on the three-tier interaction set out by Prainsack and Buyx.
When individuals decide to participate in a biobank, it is an act of Tier-1 solidarity insofar as they do so with the acceptance that certain costs will be incurred by them (or their survivors) for the sake of communal benefit. 136 Increased participation will be facilitated by attitudinal change; people must be encouraged to internalise solidarity and to accept the responsibility to act, for values are most commonly operationalised when they are internalised and embraced by publics. 137 This can be done through public campaigns highlighting the prevalence of brain conditions, the pivotal role of brain banks in the treatment of same, and the benefits of research participation. 138 While some question the propriety and effectiveness of 'nudge' policies, 139 their use of sociology, behavioural economics, and social psychology is a practical way to rationally structure choice architecture so socially useful outcomes can be achieved. 140 It has already been pointed out that the problem of countervailing nudges must be overcome if such campaigns are to work. 141 Obviously, that countervailing push should not come from regulation. Indeed, we argue that the campaigns could be statutorily dictated, as has been done in Wales with respect to transplantation; the Human Transplantation of Organs (Wales) Act 2013 imposes a duty on Welsh Ministers to promote transplantation and encourage donations deemed necessary for the improvement of the health of the people of Wales. 142 Tier-2 solidarity is implicated by how the bank structures its decision-making, how it shapes its relationship and interactions with the public, and how it communicates. 143 The bank must view its donors (and more specifically their surviving family members) as partners in the research endeavour to whom the bank owes certain duties important to the maintenance of trust, and it must structure its governance and interactions as such. 144 This also has state implications. First, more optimal and transparent biobank structures and governance arrangements could be statutorily shaped. Second, a magnitude change in donation would demand a firm commitment by the state to provide sufficient financial support to ensure that resources and personnel are available to manage that increased donation. 145 This is particularly important because the agreement to donate (ie: to bear that cost) must be met with effective measures to make that donation meaningful. If efforts or resources are wasted, public mistrust could justifiably set in.
An example of how tier-3 might be engaged is when solidarity is used to shape statutory structures so that they are more reflective of public goods and the public interest. 146 The law should explicitly adopt solidarity as a guiding value in an effort to make a positive difference in recruitment practices and participation levels. Solidarity can be relied on to:
• more stoutly vindicate the wishes of a deceased to donate in the face of resistance by survivors (ie: the use of solidarity to better operationalise autonomy); and • more openly override the deceased's (or survivors') decision to not donate in limited circumstances (such as when the individual has a rare disease that has become the target of research, or where brain banks make a specific call for 'normal' brains).
In furtherance of this, we suggest that 'authorisation' is the most appropriate decisional mechanism, and that, to work optimally, that mechanism must stipulate discourses which encourage all parties to consciously consider the public good of health, the public interest in (brain) banking, and the fundamental value of 'solidarity' in the exercise of their autonomy. In other words, it must inject some non-risk-based decisional criteria into the interaction in recognition of the fact that the individual risks of participating in biobanks are minimal (and not commensurate with participating in more tradition trial-based research). 147 Additionally, parties must be assigned authority commensurate with their interest in the cadaver. Obviously, the first interest holder is the deceased insofar as she wishes to donate and has made that wish known. This conscious choice, made when the deceased was a living, rights-bearing individual with autonomy interests, benefits the many and so, despite the above-noted evaporation of interests upon death, should, in the round, be respected. Not only does this respect reflect the value we-the public -placed on the individual when she was alive, it might also be characterised (cautiously) as a 'memorial right', meaning a right that was held and exercised in life that should be (and can only be) vindicated after death. As such, it is important to acknowledge that it is the (deceased) individual's right, not the family's right, and it should be seen as vesting upon death with the public, thereby enhancing the possibility of vindication. 148 In all other situations, the interest ranking must run from public, down to family, down to deceased. This acknowledges how decisional autonomy in relation to the corpse falls away upon the individual's death, and that the most interested remaining party is the public. Others-who have no strong principled interest in the corpse other than beliefs grounded in religion, superstition, or revulsion-should not hold a veto unless their objection is based on reliable evidence that the deceased objected to donation. Again, a provision similar to that in the Human Transplantation of Organs (Wales) Act 2013 relating to families would be useful. 149 This position is supported by Harris, who argues that, if we are to presume anything of the deceased, we should presume that he or she would have wished to donate; it is right to assume that the 147 For a brief discussion of the risks, see B Prainsack and A Buyx, n 93 above. 148 Again, and importantly, we are not proposing a framework for mandatory donation, but rather a conceptual change to the framework founded on solidarity. Under such a framework, active individual contribution and attitudinal change surrounding donation and medical research generally are encouraged, and such is supported by the above. 149 See s 4.4(4) HTOWA 2013, and discussion of this at n 14 above. deceased had no interest in frustrating knowledge or increasing the probability of others' death. 150 In addition to altering how donation is broached and supported, a solidarity approach would have implications for consent documents (and re-consent for new uses of the samples). Rather than over-emphasise risks, the consent process and its documentation would make greater efforts to highlight the benefits of donation and to inform parties about how the bank has structured its governance, oversight, and access policies so as to maximise utility and transparency, and to minimise and then appropriately manage risks. It would demand admitting to potential donors that neither recruiters nor bank custodians can know all possible uses or research directions, and that the donor would be agreeing to participate in a context of uncertainty. 151 It would emphasise the values and goals of the bank to which the donor would be contributing, and the Agreement to Participate could: 152
• acknowledge that the donor has considered the possible advantages and disadvantages of participation, including worst-case scenarios; • articulate that the surviving representative would be entitled to continue a dialogue with the bank on an ongoing basis; and • stipulate that the bank can use the tissue for research purposes into the future, including for unforeseen or changing research aims so long as they comply with the clearly stated values or mission of the bank.
This approach, which shares some characteristics with previously discussed 'consent as a propositional attitude' and 'participation as a public interest' approaches, 153 vindicates autonomy within a solidarity framework that grants banks the flexibility needed to remain viable and effective over time.
VI. CONCLUSION Neurological diseases are on the rise worldwide, and so research aimed at understanding and alleviating them will play an increasingly critical role in human health and wellbeing, and on the capacity of public healthcare systems to cope with demands. Brain banks are essential to that undertaking. However, for brain banks to deliver on their promises, there must be a shift in how we think about brain banking. The consent model under the HTA 2004 has a number of shortcomings, most notably the tension provoked by the individualistic nature of consent, which fails to offer any space for consideration of the community-enhancing aims of brain banking. While the 150 J Harris, n 58 above, 540. 151 See B Prainsack and A Buyx, n 128 above, at 6.14 and 6.23. In such a case, as noted by Prainsack and Buyx, the initial disclosure must offer individuals information as to both the broad aims/aspirations of the brain bank and the known research questions currently pursued, its funding and governance structures, its process for dealing with personal information, its commercialisation strategy (if any), and a statement that the brain bank may be used for purposes which have not yet been envisaged but for which ethics approval would have to be obtained. 152 For more on a solidarity-based approach to recruitment for biobanks and what such an approach might demand, see S Harmon, n 3 above, and B Prainsack and A Buyx, n 93 above. 153 See S Harmon, Ibid, for the latter, and O O'Neill, n 85 above, for the former.
authorisation model under the HTSA 2006 is arguably even more autonomy-centred, it might be viewed as an improvement. 154 However, its reliance on the same narrow value foundation as the HTA 2004 means that it also fails to express the values most advantageous to banking and to truly reify the difference that authorisation was supposed to achieve.
The statutory frameworks would benefit (and so would the biobanking enterprise and society) from a greater emphasis on solidarity as a guiding value. Discussions which include explicit references to solidarity (in addition to autonomy and risk) remind us that we are part of a broader community, and that individuals have (and should fulfil) obligations towards that community. Incorporating solidarity into our legislative frameworks and recruitment practices would better respect the wishes of the deceased (in cases where those wishes are now being overridden by family members), and would better realise the public interest and public goods that are at play. In this regard, it behoves us to make every effort to maximise the public investment that has been made in these resources, and to advance the public interest that brain banks underwrite.
A solidarity-grounded regime might offer solutions to some of the recurrent challenges or practical questions faced by brain banks. Having reference to the questions posed in the Introduction, we might argue as follows.
Who should consent in the absence of the expressed wishes of the deceased? Drawing on an assumption that people wish to contribute positively to society and to facilitate scientific knowledge as a public good (and indeed the public good), and that they are (or should be) supportive of ethical research and donation thereto (and this assumption is reinforced by their acceptance of the fruits of medical research), the Coroner or Procurator Fiscal should consent to donation for research when they have care of a cadaver, and they should be able to trump most objections raised by the family in other situations. In short, solidarity supports public authorities having greater power to prevail if there is a variance of views as to what should be done with the deceased's brain when the deceased has been silent as to donation.
If the known wishes of the deceased conflict with those of the family, who prevails? If there are conflicting views as between the deceased (wishing to donate) and surviving family members (wishing to preserve the corpse intact), there should again be a presumption in favour of donation which is in the 'public good'; indeed, this does nothing more than vindicate the autonomous choice of the deceased, an outcome which the deceased would have expected (and presumably did expect when s/he was alive).
If investigation emerge post-donation; it should ensure that the agreement to donate means donating to the brain bank, with all that that entails, not to a specific research target. The bank's governance structure, in turn, should be such as to ensure transparency of decision-making, clarity around and ease of access, and availability of information to the public (ie: it should have an accessible communications element). 155 Obviously, a key component of the legal and decisional framework would be transparency. This is not a strong feature in existing regimes because neither the decisional hierarchies nor the factors which go into arriving at decisions are clear. Improved transparency would encourage solidarity and make clearer to people how biobanks aim to realise reciprocity, another important driving value in this field. By embedding solidarity in the legal framework for brain donation and shifting the focus from the risks of donation (which are limited in the cadaveric context) to the opportunity presented for individuals to contribute to the health and legacy of future generations, a more sustained commitment to, and realisation of, the public good will be possible, and could be actively encouraged. 156 
